Vitamin D3 and D2 Similarly Effective for SHPT in CKD

Share this content:
Researchers found no significant difference between ergocalciferol and cholecalciferol in maintaining levels of vitamin D, parathyroid hormone, and calcium.
Researchers found no significant difference between ergocalciferol and cholecalciferol in maintaining levels of vitamin D, parathyroid hormone, and calcium.
The following article is part of conference coverage from the NKF 2018 Spring Clinical Meetings in Austin hosted by the National Kidney Foundation. Renal & Urology News staff will be reporting on medical studies conducted by nephrologists and other specialists who are tops in their field in chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from NKF 2018.

AUSTIN, Texas—For patients with stage 3 to 4 chronic kidney disease (CKD) not on dialysis who receive vitamin D therapy for secondary hyperparathyroidism, ergocalciferol (D2) and cholecalciferol (D3) appear similarly effective, according to new study findings presented at the National Kidney Foundation's 2018 Spring Clinical Meetings. But D3 might be associated with an excess risk.

Sang-A Yun, PharmD, and his collaborators from Purdue University College of Pharmacy and Indiana University Health Arnett in Lafayette, Indiana, compared outcomes between 33 patients taking D3 and 6 patients taking D2 from a single center. After 6 to 12 months of treatment, investigators found no significant difference in vitamin D, parathyroid hormone, or calcium levels between groups. Patients receiving D3, however, had a significant increase in phosphorus. Mean serum phosphorus rose 0.12 mg/dL from baseline in the D3 group, whereas it declined 0.3 mg/dL in the D2 group.

“As mortality has been shown to be associated with high phosphorous concentrations in other studies, further studies may be warranted to evaluate mortality,” Dr Yun and his colleagues concluded.

With regard to study limitations, the authors pointed out that the study was performed at a single center, so the generalizability of the findings is limited. In addition, many patients were excluded from the study, although the sample size was large enough to determine a statistically significant difference between the therapies.

See more coverage from the National Kidney Foundation Spring Clinical meeting

Reference

Yun SA, Al-Makki A, Overholser B, Shepler B. Ergocalciferol versus cholecalciferol in non-dialysis dependent chronic kidney disease patients: a retrospective cohort study. Poster presented at the National Kidney Foundation's 2018 Spring Clinical Meetings in Austin, Texas, April 10-14, 2018. Poster 177.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters